Cathie Wood’s ARK shifts focus: AMD stock sold, Nvidia and Broadcom bought

On Friday, August 28th, 2026, Cathie Wood's ARK ETF disclosed notable shifts in its technology and biotechnology investments. The most significant action was the sale of AMD stock, with the sale of 156,286 shares across multiple ETFs totaling $74,496,847. This aligns with ARK's recent pattern of reducing its AMD stake. Conversely, ARK purchased 243,707 shares of Nvidia Corporation for $55,560,321, signaling optimism in Nvidia's AI and graphics processing prowess.

Broadcom Inc. also saw a substantial addition, with ARK buying 55,131 shares for $20,483,371, reinforcing its confidence in the semiconductor sector. Notably, ARK expanded its investments in genomics and biotechnology, acquiring 54,424 shares of Intellia Therapeutics for $713,498 and 213,073 shares of Veracyte for $9,641,553. Smaller transactions included a purchase of 9,755 shares of the 3iQ Solana Staking ETF for $86,819 and a minor addition of 191 shares of Scribe Therapeutics Inc for $5,508.

Conversely, ARK sold 1,425 shares of Twist Bioscience Corporation, continuing a trend of decreasing its position in this stock. These moves illustrate Cathie Wood's strategic adaptability in managing ARK's ETFs, focusing on technology and biotechnology opportunities.